We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
- Authors
Bajema, Kristina L.; Dahl, Rebecca M.; Evener, Steve L.; Prill, Mila M.; Rodriguez-Barradas, Maria C.; Marconi, Vincent C.; Beenhouwer, David O.; Holodniy, Mark; Lucero-Obusan, Cynthia; Brown, Sheldon T.; Tremarelli, Maraia; Epperson, Monica; Mills, Lisa; So Hee Park; Rivera-Dominguez, Gilberto; Gomez Morones, Rosalba; Ahmadi-Izadi, Ghazal; Deovic, Rijalda; Mendoza, Chad; Chan Jeong
- Abstract
The mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech) provide strong protection against severe COVID-19, including hospitalization, for at least several months after receipt of the second dose (1,2). However, studies examining immune responses and differences in protection against COVID-19-associated hospitalization in real-world settings, including by vaccine product, are limited. To understand how vaccine effectiveness (VE) might change with time, CDC and collaborators assessed the comparative effectiveness of Moderna and Pfizer-BioNTech vaccines in preventing COVID-19-associated hospitalization at two periods (14-119 days and ≥120 days) after receipt of the second vaccine dose among 1,896 U.S. veterans at five Veterans Affairs medical centers (VAMCs) during February 1-September 30, 2021. Among 234 U.S. veterans fully vaccinated with an mRNA COVID-19 vaccine and without evidence of current or prior SARS-CoV-2 infection, serum antibody levels (anti-spike immunoglobulin G [IgG] and anti-receptor binding domain [RBD] IgG) to SARS-CoV-2 were also compared. Adjusted VE 14-119 days following second Moderna vaccine dose was 89.6% (95% CI = 80.1%-94.5%) and after the second Pfizer-BioNTech dose was 86.0% (95% CI = 77.6%-91.3%); at ≥120 days VE was 86.1% (95% CI = 77.7%-91.3%) for Moderna and 75.1% (95% CI = 64.6%-82.4%) for Pfizer-BioNTech. Antibody levels were significantly higher among Moderna recipients than Pfizer-BioNTech recipients across all age groups and periods since vaccination; however, antibody levels among recipients of both products declined between 14-119 days and ≥120 days. These findings from a cohort of older, hospitalized veterans with high prevalences of underlying conditions suggest the importance of booster doses to help maintain long-term protection against severe COVID-19.†.
- Publication
MMWR: Morbidity & Mortality Weekly Report, 2021, Vol 70, Issue 49, p1700
- ISSN
0149-2195
- Publication type
journal article
- DOI
10.15585/mmwr.mm7049a2